A new publication addressing TB-500 was released on July 1, 2026. The article, titled "Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards," appeared in the International Journal of Pharmaceutical Compounding.
The publication focuses on PCAC recommendations and industry safety standards as they relate to synthetic peptides used in pharmacy compounding. TB-500 remains classified as an unapproved research compound.
No specific findings, results, or conclusions from the publication were provided in the available event data. This brief reports only that the publication exists and where it appeared, without characterizing its content further.
Readers interested in TB-500 can consult the compound overview for additional context on its regulatory status and background.